Pulmonary-Vein Isolation for Atrial Fibrillation in Patients with Heart Failure
Top Cited Papers
- 23 October 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (17), 1778-1785
- https://doi.org/10.1056/nejmoa0708234
Abstract
Pulmonary-vein isolation is increasingly being used to treat atrial fibrillation in patients with heart failure. In this prospective, multicenter clinical trial, we randomly assigned patients with symptomatic, drug-resistant atrial fibrillation, an ejection fraction of 40% or less, and New York Heart Association class II or III heart failure to undergo either pulmonary-vein isolation or atrioventricular-node ablation with biventricular pacing. All patients completed the Minnesota Living with Heart Failure questionnaire (scores range from 0 to 105, with a higher score indicating a worse quality of life) and underwent echocardiography and a 6-minute walk test (the composite primary end point). Over a 6-month period, patients were monitored for both symptomatic and asymptomatic episodes of atrial fibrillation. In all, 41 patients underwent pulmonary-vein isolation, and 40 underwent atrioventricular-node ablation with biventricular pacing; none were lost to follow-up at 6 months. The composite primary end point favored the group that underwent pulmonary-vein isolation, with an improved questionnaire score at 6 months (60, vs. 82 in the group that underwent atrioventricular-node ablation with biventricular pacing; P<0.001), a longer 6-minute-walk distance (340 m vs. 297 m, P<0.001), and a higher ejection fraction (35% vs. 28%, P<0.001). In the group that underwent pulmonary-vein isolation, 88% of patients receiving antiarrhythmic drugs and 71% of those not receiving such drugs were free of atrial fibrillation at 6 months. In the group that underwent pulmonary-vein isolation, pulmonary-vein stenosis developed in two patients, pericardial effusion in one, and pulmonary edema in another; in the group that underwent atrioventricular-node ablation with biventricular pacing, lead dislodgment was found in one patient and pneumothorax in another. Pulmonary-vein isolation was superior to atrioventricular-node ablation with biventricular pacing in patients with heart failure who had drug-refractory atrial fibrillation. (ClinicalTrials.gov number, NCT00599976.)This publication has 19 references indexed in Scilit:
- Pulmonary vein antrum isolationHeart Rhythm, 2006
- Reversal of Left Ventricular Dysfunction Following Ablation of Atrial FibrillationJournal of Cardiovascular Electrophysiology, 2006
- How to do circular mapping catheter-guided pulmonary vein antrum isolation: The Cleveland Clinic approachHeart Rhythm, 2006
- Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial FibrillationJAMA, 2005
- Catheter Ablation for Atrial Fibrillation in Congestive Heart FailureNew England Journal of Medicine, 2004
- Electrophysiologic and clinical consequences of linear catheter ablation to transect the anterior left atrium in patients with atrial fibrillationHeart Rhythm, 2004
- Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic functionJournal of the American College of Cardiology, 2004
- Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillationJournal of the American College of Cardiology, 2003
- Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Pulmonary Venous FociCirculation, 2000
- Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary VeinsNew England Journal of Medicine, 1998